4.5 Article

Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches

Journal

CURRENT PHARMACEUTICAL DESIGN
Volume 20, Issue 35, Pages 5619-5633

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612820666140306095106

Keywords

Aging; sarcopenia; metabolic syndrome; renal diseases; cardiac diseases; neurodegenerative diseases

Funding

  1. Ministerio de Ciencia e Innovacion [SAF2008-01338]
  2. Biomedical Network Research Center for Rare Diseases (CIBERER)

Ask authors/readers for more resources

Mitochondrial biogenesis (MB) is the essential mechanism by which cells control the number of mitochondria. Cells respond to different physiologic, metabolic, and pathologic changes by regulating this organelle with high morphological and functional adaptability. A considerable number of proteins, transcription factors, upstream regulatory proteins and secondary mechanisms are involved in MB and the stabilization of new mitochondrial DNA. These MB activators and regulators, including the main participating proteins (e.g. PGC-1 alpha and mtTFA), are candidates for therapeutic intervention in diverse diseases, like neurodegenerative disorders, metabolic syndrome, sarcopenia, cardiac pathophysiology and physiological processes like aging. In this review, we analyze the implication of MB in several diseases in which the MB pathway is affected. Furthermore, we describe therapeutical interventions on MB targets to boost MB for the prevention and treatment of human diseases. Furthermore, evidence based results and the knowledge gained during last years for some of these drugs aim us hypothesize about the value of a given treatment involved in the activation of MB.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available